Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination

Annals of Anatomy

Volumn 198, Issue , 2015, Pages 11-20

  El Akabawy, Gehan ^a   Rashed, Laila Ahmed ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Bone marrow derived mesenchymal stem cells; Cuprizone; Demyelination; Intravenous; Transplantation

Indexed keywords

CUPRIZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CELL ULTRASTRUCTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMYELINATION; ENGRAFTMENT; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; REMYELINIZATION; ANIMAL; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CELL DIFFERENTIATION; CELLS, CULTURED; CUPRIZONE; DISEASE MODELS, ANIMAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84946903046     PISSN: 09409602     EISSN: 16180402     Source Type: Journal    
DOI: 10.1016/j.aanat.2014.12.002     Document Type: Article

References (55)

1. Acs P., Selak M.A., Komoly S., Kalman B. Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model. J. Neuroimmunol. 2013, 262:128-131.
2. Anjos-Afonso F., Bonnet D. Isolation, culture, and differentiation potential of mouse marrow stromal cells. Curr. Protoc. Stem Cell Biol. 2008, (Chapter 2 Unit 2B 3). 10.1002/9780470151808.sc02b03s7.
3. Auletta J.J., Bartholomew A.M., Maziarz R.T., Deans R.J., Miller R.H., Lazarus H.M., Cohen J.A. The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy 2012, 4:529-547.
4. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., Miller R.H. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57:1192-1203.
5. Bai L., Lennon D.P., Caplan A.I., Dechant A., Hecker J., Kranso J., Zaremba A., Miller R.H. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15:862-870.
6. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
7. Ben-Hur T., Fainstein N., Nishri Y. Cell-based reparative therapies for multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2013, 13:397.
8. Compston0 A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
9. Devine S.M., Cobbs C., Jennings M., Bartholomew A., Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101:2999-3001.
10. Doan V., Kleindienst A.M., Mcmahon E.J., Long B.R., Matsushima G.K., Taylor L.C. Abbreviated exposure to cuprizone is sufficient to induce demyelination and oligodendrocyte loss. J. Neurosci. Res. 2013, 91:363-373.
11. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S22-S31. (discussion S43-54).
12. Fancy S.P., Chan J.R., Baranzini S.E., Franklin R.J., Rowitch D.H. Myelin regeneration: a recapitulation of development?. Annu. Rev. Neurosci. 2011, 34:21-43.
13. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
14. Foudah D., Monfrini M., Donzelli E., Niada S., Brini A.T., Orciani M., Tredici G., Miloso M. Expression of neural markers by undifferentiated mesenchymal-like stem cells from different sources. J. Immunol. Res. 2014, 2014:987678.
15. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., Mantegazza R., Frassoni F., Mancardi G., Pedotti R., Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 2007, 61:219-227.
16. Gordon D., Pavlovska G., Uney J.B., Wraith D.C., Scolding N.J. Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 2010, 69:1087-1095.
17. Gudi V., Gingele S., Skripuletz T., Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front. Cell. Neurosci. 2014, 8:73.
18. Guy J., Ellis E.A., Kelley K., Hope G.M. Spectra of G ratio, myelin sheath thickness, and axon and fiber diameter in the guinea pig optic nerve. J. Comp. Neurol. 1989, 287:446-454.
19. Hiremath M.M., Chen V.S., Suzuki K., Ting J.P., Matsushima G.K. MHC class II exacerbates demyelination in vivo independently of T cells. J. Neuroimmunol. 2008, 203:23-32.
20. Howell O.W., Rundle J.L., Garg A., Komada M., Brophy P.J., Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:1017-1033.
21. Jadasz J.J., Aigner L., Rivera F.J., Kury P. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis. Cell Tissue Res. 2012, 349:331-347.
22. Jaramillo-Merchan J., Jones J., Ivorra J.L., Pastor D., Viso-Leon M.C., Armengol J.A., Molto M.D., Geijo-Barrientos E., Martinez S. Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. Cell Death Dis. 2013, 4:e779.
23. Jensen E.C. Quantitative analysis of histological staining and fluorescence using Image. J. Anat. Rec. (Hoboken) 2013, 296:378-381.
24. Jorgensen C., Djouad F., Apparailly F., Noel D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther. 2003, 10:928-931.
25. Kassis I., Grigoriadis N., Gowda-Kurkalli B., Mizrachi-Kol R., Ben-Hur T., Slavin S., Abramsky O., Karussis D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch. Neurol. 2008, 65:753-761.
26. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
27. Lanza C., Morando S., Voci A., Canesi L., Principato M.C., Serpero L.D., Mancardi G., Uccelli A., Vergani L. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J. Neurochem. 2009, 110:1674-1684.
28. Lu Z., Hu X., Zhu C., Wang D., Zheng X., Liu Q. Overexpression of CNTF in mesenchymal stem cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J. Neuroimmunol. 2009, 206:58-69.
29. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
30. Mahmood A., Lu D., Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J. Neurotrauma 2004, 21:33-39.
31. Matysiak M., Orlowski W., Fortak-Michalska M., Jurewicz A., Selmaj K. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J. Neuroimmunol. 2011, 233:106-111.
32. Mcmahon E.J., Suzuki K., Matsushima G.K. Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J. Neuroimmunol. 2002, 130:32-45.
33. Morando S., Vigo T., Esposito M., Casazza S., Novi G., Principato M.C., Furlan R., Uccelli A. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res. Ther. 2012, 3:3.
34. Mostafavi F.S., Razavi S., Mardani M., Esfandiari E., Esfahani H.Z., Kazemi M. Comparative study of microtubule-associated protein-2 and glial fibrillary acidic proteins during neural induction of human bone marrow mesenchymal stem cells and adipose-derived stem cells. Int. J. Prev. Med. 2014, 5:584-595.
35. Nessler J., Benardais K., Gudi V., Hoffmann A., Salinas Tejedor L., Janssen S., Prajeeth C.K., Baumgartner W., Kavelaars A., Heijnen C.J., Van Velthoven C., Hansmann F., Skripuletz T., Stangel M. Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS ONE 2013, 8:e69795.
36. Payne N., Siatskas C., Barnard A., Bernard C.C. The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis. Curr. Stem Cell Res. Ther. 2011, 6:50-62.
37. Plant S.R., Arnett H.A., Ting J.P. Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination. Glia 2005, 49:1-14.
38. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., Yuan S., Young Y.K., Boivin M.N., Forner K., Basik M., Galipeau J. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009, 182:5994-6002.
39. Raine C.S., Scheinberg L.C. On the immunopathology of plaque development and repair in ultiple sclerosis. J. Neuroimmunol. 1988, 20:189-201.
40. Raivich G., Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res. Brain Res. Rev. 2004, 46:261-281.
41. Rangan G.K., Tesch G.H. Quantification of renal pathology by image analysis. Nephrology (Carlton) 2007, 12:553-558.
42. Rasmussen S., Imitola J., Ayuso-Sacido A., Wang Y., Starossom S.C., Kivisakk P., Zhu B., Meyer M., Bronson R.T., Garcia-Verdugo J.M., Khoury S.J. Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann. Neurol. 2011, 69:878-891.
43. Rawji K.S., Yong V.W. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin. Dev. Immunol. 2013, 2013:948976.
44. Singh S.P., Tripathy N.K., Nityanand S. Comparison of phenotypic markers and neural differentiation potential of multipotent adult progenitor cells and mesenchymal stem cells. World J. Stem. 2013, 5:53-60.
45. Sloka S., Metz L.M., Hader W., Starreveld Y., Yong V.W. Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J. Neuroinflamm. 2013, 10:89.
46. Stagg J., Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr. Mol. Med. 2013, 13:856-867.
47. Tsiperson V., Li X., Schwartz G.J., Raine C.S., Shafit-Zagardo B. GAS6 enhances repair following cuprizone-induced demyelination. PLoS ONE 2010, 5:e15748.
48. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol. 2007, 28:219-226.
49. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011, 10:649-656.
50. Yang J., Yan Y., Ciric B., YU S., Guan Y., XU H., Rostami A., Zhang G.X. Evaluation of bone marrow- and brain-derived neural stem cells in therapy of central nervous system autoimmunity. Am. J. Pathol. 2010, 177:1989-2001.
51. Yang L.Y., Huang T.H., Ma L. Bone marrow stromal cells express neural phenotypes in vitro and migrate in brain after transplantation in vivo. Biomed. Environ. Sci. 2006, 19:329-335.
52. Zhang J., Li Y., Chen J., Cui Y., Lu M., Elias S.B., Mitchell J.B., Hammill L., Vanguri P., Chopp M. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol. 2005, 195:16-26.
53. Zhang J., Li Y., Lu M., Cui Y., Chen J., Noffsinger L., Elias S.B., Chopp M. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J. Neurosci. Res. 2006, 84:587-595.
54. Zhang J., Brodie C., LI Y., Zheng X., Roberts C., Lu M., Gao Q., Borneman J., Savant-Bhonsale S., Elias S.B., Chopp M. Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J. Neurol. Sci. 2009, 279:30-38.
55. Zhou C., Zhang C., Chi S., Xu Y., Teng J., Wang H., Song Y., Zhao R. Effects of human marrow stromal cells on activation of microglial cells and production of inflammatory factors induced by lipopolysaccharide. Brain Res. 2009, 1269:23-30.